How India Exports Proguanil to the World

Proguanil is primarily available in the United States as part of the combination therapy atovaquone/proguanil, marketed under the brand name Malarone. According to the FDA's Orange Book, there are multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of this combination, indicating a competitive market landscape. Notably, the FDA has not issued any import alerts specific to proguanil or its combination products, suggesting compliance with regulatory standards. Given that only 0.4% of India's proguanil exports are directed to the United States, the market presence of Indian exporters in this segment appears limited.

In the European Union, proguanil is authorized for use both as a monotherapy and in combination with atovaquone. The European Medicines Agency (EMA) oversees the approval and monitoring of these medicines, ensuring they meet stringent safety and efficacy standards. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulates proguanil-containing products. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions, ensuring product quality and safety.

Proguanil was included in the WHO Model List of Essential Medicines until September 2025, when it was removed during the 24th list update. This removal reflects evolving treatment guidelines and the availability of alternative therapies. Proguanil is recognized in various pharmacopoeias, including the British Pharmacopoeia (BP) and the European Pharmacopoeia (EP), which set quality standards for medicinal substances.

In India, proguanil is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for proguanil, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the export of pharmaceutical products.

The primary patents for proguanil have expired, leading to the availability of generic versions and increased market competition. This patent expiration has facilitated the entry of multiple manufacturers into the market, contributing to the widespread availability of the drug.

In May 2025, the WHO's 25th Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. During this meeting, proguanil was removed from the list, reflecting changes in global treatment protocols and the availability of more effective antimalarial therapies. (who.int)

In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, which no longer includes proguanil. This update underscores the shift in global health priorities and the adoption of newer antimalarial treatments. (who.int)

These developments highlight the dynamic nature of the pharmaceutical landscape and the importance of staying informed about regulatory changes and market trends.

Proguanil's active pharmaceutical ingredient (API) production in India is heavily reliant on key starting materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India. Such concentration exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in these countries.

In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing plants, causing disruptions in the supply of KSMs. For instance, in July 2018, the closure of Chinese companies impacted Indian pharmaceutical players, leading to increased prices and supply uncertainties. These events underscore the vulnerability of the supply chain due to over-reliance on a limited number of sources for critical raw materials.

Our proprietary trade data indicates that Mylan Laboratories Limited dominates Proguanil exports from India, accounting for 99.8% of the total export value between 2022 and 2026. This extreme supplier concentration poses significant risks, as any operational or compliance issues within Mylan could severely disrupt the global supply of Proguanil.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing dependency on imports for critical APIs and KSMs. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step towards self-reliance. However, the effectiveness of these initiatives in diversifying the supplier base for Proguanil remains to be seen.

Recent geopolitical tensions have severely impacted key maritime routes essential for Proguanil exports. In March 2026, escalating conflicts in the Middle East led to the closure of the Strait of Hormuz, a critical chokepoint for global shipping. This disruption halted approximately 20% of the world's daily oil supply and significantly affected maritime trade. Simultaneously, security concerns in the Red Sea prompted major shipping lines to suspend transits, leading to increased freight rates and extended transit times for shipments from India to Europe.

These disruptions have not only increased transportation costs but also heightened the risk of supply chain delays for Proguanil. While no specific shortage alerts have been issued by the FDA or EMA as of March 2026, the potential for such shortages remains high if these geopolitical tensions persist.

• Diversify Supplier Base: Encourage the development of additional manufacturing facilities for Proguanil within India and other regions to reduce reliance on a single exporter.

• Strengthen Domestic API Production: Accelerate initiatives under the PLI scheme to enhance domestic production of critical APIs and KSMs, thereby reducing dependency on imports.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the sourcing of raw materials and identify potential vulnerabilities in the supply chain.

• Develop Alternative Shipping Routes: Explore and invest in alternative maritime routes and logistics solutions to mitigate the impact of disruptions in traditional shipping lanes.

• Establish Strategic Reserves: Create and maintain strategic reserves of Proguanil and its raw materials to buffer against supply chain disruptions.

RISK_LEVEL: HIGH